Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that afflicts approximately 400,000 people in the United States alone. Currently there is no cure for MS and only seven "disease-modifying drugs" have been approved by the FDA to treat relapsing, but not primary progressive, forms of MS. Although the genetic and environmental factors that trigger the disease vary, the common pathological outcome of MS is the destruction of oligodendrocytes and their associated neuronal axons through a process called encephalomyelitis. Development of encephalomyelitis requires coordinated expression of a unique class of genes called inflammatory genes. These genes encode inflammatory proteins that mediate the activation, migration, and effector function of inflammatory cells that cause encephalomyelitis. Inhibiting the functions of this class of genes may be effective for ameliorating MS. However, because MS is mediated by many, if not all, inflammatory genes, inhibiting one or a few of them may have limited efficacies. This competitive renewal application is inspired by our recent discovery that the transcription factor c Rel, a lymphoid and myeloid member of the Rel/nuclear factor-?B (NF-?B) family, controls (i) the expression of multiple inflammatory genes, and (ii) the development of the inflammatory Th17 cells. The goal of this application is to elucidate the mechanisms through which c-Rel controls the Th17 response, and to develop c-Rel-blocking drugs for the treatment of inflammatory diseases. The hypotheses to be tested are: (i) c-Rel is a primary transcription factor of the Th17 response, and (ii) c-Rel is a prime drug target for treating multiple sclerosis.

Public Health Relevance

Information generated from these studies will not only advance our understanding of the Th17 and c-Rel biology, but also aid in developing novel c-Rel blocking drugs for the treatment of inflammatory diseases. Therefore, this project may advance both scientific knowledge and clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI050059-08A1
Application #
8370060
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Esch, Thomas R
Project Start
2001-09-01
Project End
2017-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
8
Fiscal Year
2012
Total Cost
$346,667
Indirect Cost
$130,000
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fayngerts, Svetlana A; Wu, Jianping; Oxley, Camilla L et al. (2014) TIPE3 is the transfer protein of lipid second messengers that promote cancer. Cancer Cell 26:465-78
Lou, Yunwei; Sun, Honghong; Morrissey, Samantha et al. (2014) Critical roles of TIPE2 protein in murine experimental colitis. J Immunol 193:1064-70
Ruan, Qingguo; Zheng, Shi-Jun; Palmer, Scott et al. (2010) Roles of Bcl-3 in the pathogenesis of murine type 1 diabetes. Diabetes 59:2549-57
Ludwinski, Maciej W; Sun, Jing; Hilliard, Brendan et al. (2009) Critical roles of Bim in T cell activation and T cell-mediated autoimmune inflammation in mice. J Clin Invest 119:1706-13
Ruan, Qingguo; Kameswaran, Vasumathi; Tone, Yukiko et al. (2009) Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 31:932-40
Sun, Honghong; Gong, Shunyou; Carmody, Ruaidhri J et al. (2008) TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133:415-26